Key result
Among pediatric patients treated with high-dose doxorubicin (≥300 mg/m2), acute intercurrent viral illness triggered a sudden, late decrease in fractional shortening in 5 of 7 patients.
Why the study?
Does acute intercurrent viral illness trigger late cardiotoxicity in pediatric patients previously treated with doxorubicin?
Population
30 selected pediatric patients followed after completion of doxorubicin chemotherapy
Comparison
Acute intercurrent viral illness and high-dose… vs No viral illness, or low-dose doxorubicin
Design
Cohort
Follow-up
2-10 years
Authors
Loading...
Intercurrent viral illness was not linked to late FS decline post-doxorubicin; leaves open need for prospective validation in survivors.
Cohort (n=30)
Does acute intercurrent viral illness trigger late cardiotoxicity in pediatric patients previously treated with doxorubicin?
Acute intercurrent viral illness may act as a trigger for late, sudden cardiac dysfunction in pediatric patients with subclinical cardiac damage from high-dose doxorubicin.
Ali et al. (1994) conducted a cohort in Late doxorubicin-associated cardiotoxicity (n=30). Acute intercurrent viral illness vs. No acute intercurrent viral illness was evaluated on Changes in echocardiographically measured fractional shortening (FS). Among pediatric patients treated with high-dose doxorubicin (≥300 mg/m2), acute intercurrent viral illness triggered a sudden, late decrease in fractional shortening in 5 of 7 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: